West Paces Advisors’s PTC Therapeutics PTCT Stock Holding History

West Paces Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.08K	Buy	+50	New	+$3.61K	﹤0.01%	480
2025 Q2	–	Sell	-200	Closed	-$10.2K	–	473
2025 Q1	$10.2K	Sell	200 -300	-60%	-$15K	﹤0.01%	346
2024 Q4	$22.6K	Hold	500	–	–	0.01%	294
2024 Q3	$18.6K	Hold	500	–	–	﹤0.01%	307
2024 Q2	$15.3K	Sell	500 -500	-50%	-$16.2K	﹤0.01%	314
2024 Q1	$29.1K	Hold	1,000	–	–	0.01%	279
2023 Q4	$27.6K	Hold	1,000	–	–	0.01%	275
2023 Q3	$22.4K	Buy	+1,000	New	+$37.2K	0.01%	285

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

West Paces Advisors's PTCT Position: Q2 2026 in Review

West Paces Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 50 shares worth $4.08K. The stake represents ﹤0.01% of the portfolio and ranks #480 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in PTCT as recently as Q1 2025.

West Paces Advisors first reported a position in PTCT in Q3 2023 and has held it in 8 quarters since. The position peaked at $29.1K in Q1 2024. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

West Paces Advisors held 50 shares of PTC Therapeutics worth $4.08K as of Q2 2026.
PTC Therapeutics was a new West Paces Advisors position in Q2 2026.
PTC Therapeutics made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #480 holding.
West Paces Advisors first reported a position in PTC Therapeutics in Q3 2023 and has held it in 8 quarters since.
West Paces Advisors's PTC Therapeutics position peaked at $29.1K in Q1 2024.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.